|May 16, 2014|
|06:01 EDT||WFM, AGN||Stocks with implied volatility below IV index mean; AGN WFM|
Stocks with implied volatility below IV index mean; Allergan (AGN) 26, Whole Foods (WFM) 23 according to iVolatility.
News For AGN;WFM From The Last 14 Days
|August 28, 2015|
|17:47 EDT||WFM||Whole Foods shares look cheap, Barron's reports |
With its shares down about 50% from all-time highs, Whole Foods looks cheap, Barron's reports. On average over the past five years, the shares have been twice as expensive as the S&P 500 relative to earnings, but now that premium is only about 20%, and the stock could return 20% in a year, Barron's added. Reference Link
|09:50 EDT||AGN||Allergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports|
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
|August 25, 2015|
|08:14 EDT||AGN||Allergan multiple is low, says Leerink|
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
|August 24, 2015|
|18:02 EDT||WFM||S&P 500 enters correction territory amid global growth concerns|
Subscribe for More Information
|08:37 EDT||AGN||Allergan recalls certain lots of REFRESH, FML, Blephamide treatments|
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
|August 20, 2015|
|19:53 EDT||WFM||Retailers, others question heightened fees at Port of Oakland, WSJ says|
After the Port of Oakland said it is considering implementing additional fees, the Retail Industry Leaders Association told the Federal Maritime Commission that it is "troubled" due to the lack of details regarding the fees, according to the Wall Street Journal. The retailer group also questioned the general effectiveness of such a program, and the Agriculture Transportation Coalition echoed the criticism, said the report. Note that executives from Lowe's (LOW), Best Buy (BBY), Target (TGT), Coca-Cola (KO), J.C. Penney (JCP), Tyson Foods (TSN), SunOpta (STKL), and Whole Foods (WFM) serve on the boards of the aforementioned associations. Reference Link
|10:52 EDT||WFM||Whole Foods calls active |
Whole Foods August 33 and 33.5 calls are active on total call volume of 4K contracts (3K puts) on the subject of takeover chatter. August call option implied volatility is at 32, August weekly is at 27, September is at 28; compared to its 52-week range of 17 to 43. Active call volume suggests traders taking positions for large near term price movement.
|08:16 EDT||AGN||Allergan's Botox resubmission for lower limb spasticiy accepted by FDA|
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.